Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 9 of 9 entries
View as:

The Study is Designed to Evaluate Single Ascending Doses of AR882 in Healthy Adult Males

Phase: N/A Priority: Normal
NCT ID: NCT04347005 Org: User:
Start: 01/22/19 End: 07/31/19 Due: 07/31/20

Phase 2b Evaluation of Efficacy and Safety of AR882 in Gout Patients

Phase: N/A Priority: Normal
NCT ID: NCT05119686 Org: User:
Start: 11/16/21 End: 11/17/22 Due: 11/17/23

Pharmacokinetic Study of AR882 in Subjects With Various Degrees of Renal Impairment

Phase: N/A Priority: Normal
NCT ID: NCT04646889 Org: User:
Start: 01/14/21 End: 06/27/22 Due: 06/27/23

Phase 2 to Assess Efficacy and Safety in AR882 Alone or in Combination With Allopurinol in Patients With Tophaceous Gout

Phase: N/A Priority: Normal
NCT ID: NCT05253833 Org: User:
Start: 08/12/22 End: 10/28/24 Due: 10/28/25

Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients (AR882-302)

Phase: N/A Priority: Normal
NCT ID: NCT06439602 Org: User:
Start: 06/26/24 End: 11/30/26 Due: 11/30/27

Single-dose AME Study With [14C]AR882 in Healthy Male Subjects

Phase: N/A Priority: Normal
NCT ID: NCT04508426 Org: User:
Start: 07/16/20 End: 08/12/20 Due: 08/12/21

Phase 2a Study of AR882 Alone and in Combination With Febuxostat or Allopurinol in Gout Patients

Phase: N/A Priority: Normal
NCT ID: NCT04155918 Org: User:
Start: 02/03/20 End: 09/03/20 Due: 09/03/21

Multiple Ascending Dose Study of AR882 in Healthy Adult Male Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT04314986 Org: User:
Start: 06/28/19 End: 09/18/19 Due: 09/18/20

Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients (AR882-301)

Phase: N/A Priority: Normal
NCT ID: NCT06846515 Org: User:
Start: 03/11/25 End: 04/30/26 Due: 04/30/27